Theriva Biologics has sold its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Biossil Labs for an upfront payment of $350,000 and potential milestones up to $91 million plus royalties. Biossil Labs will take over all development and commercialization responsibilities. SYN-004 aims to protect the gut microbiome during antibiotic treatment and reduce infections like C. difficile and antibiotic-resistant bacteria. The sale allows Theriva to focus on its cancer therapeutics while Biossil advances ongoing clinical trials, including a Phase 1b/2a study on preventing complications in transplant patients.
Theriva Biologics' recent sale of its SYN-004 enzyme portfolio comes as a backdrop to the health sector's activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 02, 2026 19:21 WIB: out of 150 priced US health-sector stocks, 82 rose and 47 fell. Notable movers include RLAY at USD 18.75 (+2.18%), TWST at USD 156.06 (+2.15%), and NTRA at USD 423.00 (+2.13%), with typical hold times ranging from 18 to 27 days on Pluang.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
